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These comments were delivered upon receiving the inaugu-
ral AMGEN International Prize at the World Congress of
Nephrology in Berlin, Germany, June 9, 2003.
I am extremely pleased to be named the first recipient
of the AMGEN International Prize and express my ap-
preciation to the International Society of Nephrology and
to AMGEN, Inc. for this high honor. Please be assured
that the prize recognizes the efforts of many devoted
colleagues to whom I am indebted and delighted to cite
in the references to follow. To place our studies on reno-
protection in its proper context, let me remind you that
when we began our studies in the 1970s, much of the
effort in nephrology was concerned with improving the
effectiveness of renal replacement therapies for patients
with otherwise fatal end-stage renal disease (ESRD). At
that time, we fortuitously gained access to a strain of
rats with glomeruli situated on the renal cortical surface,
accessible to direct study by new microtechniques devel-
oped in our laboratory [1]. We were therefore in the
unique position to address the following questions: What
are the precise hemodynamic forces and biophysical
properties that govern glomerular capillary function in
health? How are these elements modified by renal in-
jury? Do these modifications contribute to the relentless
progression of renal disease? If so, can they be reversed
so as to prevent or retard the development of ESRD?
When glomerular filtration rate (GFR) in humans falls
below about half of normal, further loss of function of-
ten ensues, even when the original disease becomes inac-
tive. In response to reduced renal mass, surviving neph-
rons undergo adaptations in structure and function that
raise single-nephron GFR to meet excretory demands.
In our initial study [2], we found that the glomerular
hemodynamic adaptations responsible for increased sin-
gle-nephron GFR actually proved to initiate and perpet-
uate glomerular injury following partial nephrectomy,
suggesting that similar events may occur when nephrons
are lost through disease. In addition to the detrimental
effects of acquired nephron loss [3, 4], we have also
argued that inborn deficits in total nephron number in
1163
association with low birth weight contribute to hyperten-
sion and progressive glomerular injury in adult life [5, 6],
an hypothesis now confirmed in several recent reports
[7–9].
The most unfavorable glomerular hemodynamic adap-
tation to congenital deficits or focal nephron obliteration
by disease is elevated glomerular capillary pressure, which
ultimately leads to glomerular scarring and nephron drop-
out. Among a variety of measures that slow progression
of experimental renal disease, alleviation of glomerular
capillary hypertension has been found to be the common
denominator. Meyer, Hostetter and I, working with the
partial nephrectomy model [3], and Zatz, Meyer, Rennke,
and I [10], with the streptozotocin diabetes model, showed
that dietary protein restriction reduces glomerular pres-
sure and ameliorates renal structural injury. Glomerular
capillary hypertension is maintained largely by angioten-
sin-dependent mechanisms, via increased systemic blood
pressure and efferent arteriolar vasoconstriction [11]. In
addition to their potent systemic antihypertensive actions,
angiotensin-converting enzyme (ACE) inhibitors and an-
giotensin receptor blockers (ARBs) are highly effective in
controlling glomerular capillary hypertension and thereby
in retarding disease progression. In rats with partial renal
ablation, Anderson, Rennke, and I observed that ACE
inhibitors reduced the glomerular capillary pressure gra-
dient, P, and slowed renal disease progression, as re-
flected by less proteinuria and glomerulosclerosis, whereas,
with a combination of hydralazine, reserpine, and hydro-
chlorothiazide, despite equivalent systemic blood pres-
sure lowering, glomerular hypertension persisted and
disease progression continued unabated [12]. Subsequent
studies by my group and others consistently demonstrated
renal protection with inhibitors of the renin-angiotensin
system (RAS) in a variety of experimental models of
renal injury [13].
Thus, angiotensin II emerged as a central mediator of
the glomerular hemodynamic changes associated with
progressive renal injury. It soon became apparent that
several nonhemodynamic effects of angiotensin II are
also important in mediating renal disease progression.
These include oxidant and aldosterone-induced injury,
increased filtration of plasma proteins, and coordinated
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Fig. 1. Final common pathway for progres-
sion of chronic renal disease. Angiotensin II
(ANG II) promotes injury in at least five sepa-
rate steps in the cycle. Abbreviations are: PGC,
glomerular capillary pressure; SNGFR, single-
nephron glomerular filtration rate (GFR); GS,
glomerulosclerosis; TIF, tubulointerstitial fi-
brosis; FSGS, focal segmental glomeruloscle-
rosis; NF-B, nuclear factor-kappaB; PAI-1,
plasminogen activation inhibitor-1; TGF-,
transforming growth factor-; CTGF, connec-
tive tissue growth factor; CAMs, cell adhesion
molecules.
nuclear factor-kappa B (NF-B)–induced up-regulation
of cytokines, chemokines, transforming growth factor-
(TGF-), connective tissue growth factor (CTGF), and
chemotactic and cell adhesion molecule expression, all
of which in turn give rise to mesangial cell proliferation,
increased synthesis of extracellular matrix proteins, stim-
ulation of plasminogen activation inhibitor-1 production
by endothelial and vascular smooth muscle cells, and mac-
rophage activation and infiltration [14–17]. Together, these
factors promote focal and global glomerulosclerosis and
tubulointerstitial fibrosis, culminating in further nephron
loss and a vicious cycle or final common pathway of pro-
gressive renal damage (Fig. 1).
I will now review the key clinical trials that have ema-
nated from these studies in experimental animals. Our
initial studies in the partial nephrectomy model showing
that dietary protein restriction abrogates the adaptive
rise in glomerular pressure and slows the tendency to
renal disease progression helped motivate the National
Institutes of Health Modification of Diet in Renal Dis-
ease (NIH-MDRD) trial. Although the overall study re-
sults reported by Klahr et al [18] were ambiguous, subse-
quent subgroup analyses by Levey et al [19, 20] provided
clear evidence of benefit from dietary protein restriction.
Furthermore, a meta-analysis of ten randomized, con-
trolled studies of the effects of protein restriction on the
progression of diabetic and nondiabetic renal disease by
Pedrini et al [21] determined that the overall relative
risk of renal failure or death was indeed reduced with
protein restriction, as compared with nonrestricted pro-
tein intake.
With regard to pharmacologic approaches, our studies
in rodents, showing that control of glomerular capillary
hypertension with ACE inhibitors retards the develop-
ment of glomerular lesions of experimental diabetic ne-
phropathy [22], soon motivated a number of clinical tri-
als. Results of several small clinical studies performed
to assess the effects of antihypertensive treatment in
general, and ACE inhibitors in particular, on the rate
of progression of diabetic nephropathy appeared to show
a favorable response to therapy. However, none was
sufficiently robust statistically to establish benefit conclu-
sively. These shortcomings were resolved by the clinical
trial entitled “The Effect of Angiotensin-Converting En-
zyme Inhibition on Diabetic Nephropathy” performed
by the Collaborative Study Group led by Dr. Edmund
Lewis [23]. A total of 407 patients with type 1 diabetes
and proteinuria (500 mg/day) were randomized to re-
ceive either the ACE inhibitor, captopril, or placebo. If
needed, blood pressure was managed independently of
the experimental treatment, using agents other than
ACE inhibitors or calcium channel blockers. Captopril
treatment was associated with a 50% reduction in the
combined risk of ESRD or death. These results yielded
solid clinical proof of the concept that ACE inhibitors
provide effective retardation of nephropathy, in this case
due to type 1 diabetes, and led to the first federally
approved treatment in the United States for slowing the
progression of kidney disease.
It must be noted, however, that most diabetic patients
who develop ESRD suffer from type 2 diabetes, reflect-
ing its approximately 20-fold greater prevalence over
type 1 diabetes. Type 2 diabetic patients develop glomer-
ular hyperfiltration, proteinuria, and progressive declines
in GFR, much as in type 1 diabetes and with essentially
the same time course. Most renal protection studies with
ACE inhibitors demonstrated significant reduction in
proteinuria but failed to address the hard end point of
ESRD, as these trials generally enrolled patients at rela-
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tively early stages of diabetic nephropathy and their du-
rations were usually 2 years or less.
Since 1995, ARBs have also been available to inhibit
the RAS, by blocking angiotensin II subtype 1 (AT1)
receptors. Thus, whereas ACE inhibitors depress ACE-
dependent angiotensin II production, ARBs block the
effects of angiotensin II from any source at the receptor
level. Despite these differences in mechanisms of action,
experimental studies reveal that ACE inhibitors and
ARBs produce similar improvements in glomerular he-
modynamics and afford equivalent renoprotection in a
variety of experimental models of kidney disease [13].
Two large, recently completed, prospective, multicen-
ter, randomized clinical trials showed that interruption
of the RAS with ARBs in type 2 diabetic patients with
overt nephropathy delays the progression of renal dis-
ease. The Irbesartan Type 2 Diabetic Nephropathy Trial
(IDNT) evaluated the effects of the ARB, irbesartan,
on renal and cardiovascular morbidity and mortality ver-
sus the effects of conventional therapy (placebo group)
or the calcium channel blocker, amlodipine, in 1715 sub-
jects [24]. The primary composite end point of the study
was the time to a first event, namely, doubling of baseline
serum creatinine, ESRD, or death from any cause. For
subjects receiving irbesartan, the adjusted relative risk
of reaching the primary composite end point was 20%
lower than for those receiving placebo and 23% lower
than for those receiving amlodipine. There was no sig-
nificant difference between placebo and amlodipine for
the primary composite end point. The relative risk of
ESRD in the irbesartan group was 17% lower that that
in the placebo group and 24% lower than that in the
amlodipine group, but these differences did not achieve
statistical significance. Secondary cardiovascular out-
comes also failed to show significant differences among
the various arms of the IDNT study. Proteinuria was
reduced an average of 33% in the irbesartan arm, com-
pared with 6% and 10% in the amlodipine and placebo
arms, respectively. The more favorable renal outcomes
in the irbesartan group were in excess of effects directly
attributable to blood pressure control.
The Reduction of End Points in NIDDM With the
Angiotensin II Antagonist Losartan (RENAAL) study
was also undertaken to determine whether the ARB,
losartan, reduces the number of patients with type 2
diabetes who experience a doubling of serum creatinine,
ESRD or death, as compared with placebo-treated sub-
jects [25]. The primary and secondary end points of the
study were similar to those in the IDNT study, but treat-
ment was of longer average duration in the RENAAL
study (3.4 vs. 2.6 years). In RENAAL, 1513 subjects
were randomized to receive either losartan or placebo
once daily on a background of conventional antihyper-
tensive therapy, excluding ACE inhibitors or other ARBs.
Losartan treatment significantly reduced the risk of the
primary composite end point by 16% relative to placebo.
Losartan lowered the risk of doubling of serum creati-
nine, the risk of reaching ESRD, and the combined risk
of ESRD or death by 25%, 28%, and 20%, respectively,
relative to placebo. RENAAL is thus the only study to
date to specifically reduce the risk of ESRD in diabetes,
in this case with losartan. Proteinuria declined by 35%
in the losartan arm and increased slightly in the placebo
group, and losartan slowed the estimated rate of loss of
GFR by 18% relative to placebo. No significant differ-
ence was observed between the losartan and placebo
arms for the secondary composite end point of cardiovas-
cular morbidity or mortality, or for most of the cardiovas-
cular components, although the losartan arm showed a
significant reduction of 32% in the risk of a first hospital-
ization for heart failure. Once again, these consistent
benefits of losartan in the RENAAL study were above
and beyond effects that could be attributed to measured
reductions in blood pressure.
Several studies investigated the potential of ACE in-
hibitors to afford renoprotection in nondiabetic forms
of clinical renal disease. In the Angiotensin-Converting-
Enzyme Inhibition in Progressive Renal Insufficiency
(AIPRI) trial, Maschio et al [26] randomly assigned 583
patients with renal disease of diverse etiologies to treat-
ment with benazepril or placebo. After 3 years of follow-
up, the study found a 53% reduction with ACE inhibitor
treatment in the combined risk of doubling of the base-
line serum creatinine or need for dialysis. However, a
significantly lower blood pressure among patients receiv-
ing ACE inhibitor versus placebo made it difficult to
separate the beneficial effects of blood pressure reduc-
tion from any unique renoprotective effects of ACE inhi-
bition.
In the more recent Ramipril Efficacy in Nephropathy
(REIN) study [27], 352 patients with nondiabetic renal
disease, randomly assigned to receive either ACE inhibi-
tor or placebo, achieved similar control of blood pres-
sure. Among patients with proteinuria of at least 3g/day
at baseline, a significantly lower rate of decline of GFR
was seen after 2 years in patients receiving the ACE
inhibitor, ramipril (0.44 vs. 0.81 mL/min/month with
non-ACE conventional therapy). In the extension phase
of the study [28], patients who initially received placebo
were switched to ACE inhibitors, and those already on
ACE inhibitors continued this treatment. Consistent
with the findings in the first 2-year phase of the study,
those switched from conventional therapy to ramipril
treatment enjoyed a significant reduction in the rate of
GFR decline, while patients continuing on the ACE in-
hibitor enjoyed a further reduction in the rate of GFR
decline to levels similar to those associated with normal
aging. Indeed, from 36 to 54 months of follow-up, no
patients in the latter group reached ESRD, and a small
number actually experienced a rise in GFR [29]. Another
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186 REIN study patients with less that 3 g/day of protein-
uria at baseline also benefited from ramipril with reduced
incidence of ESRD [30].
In the AIPRID data study, a recent patient-based meta-
analysis of 1860 nondiabetic subjects from 11 randomized
ACE inhibitor versus placebo-treatment trials, Jafar et al
[31] also concluded that ACE inhibitors are more effec-
tive that other antihypertensive treatment regimens in
slowing renal disease progression and reducing protein-
uria. Significantly lower values were seen with ACE in-
hibitors for several outcome measures, including level of
proteinuria and incidence of ESRD. A similar conclusion
emerged from the AASK trial in hypertensive African
Americans [32], in which ramipril proved more renopro-
tective that the comparator drugs, amlodipine or meto-
prolol.
In addition to the renoprotective effects of ACE inhib-
itor treatment, the recent Heart Outcomes Prevention
Evaluation (HOPE) [33] and Losartan Intervention for
End Point Reduction in Hypertension Study (LIFE) [34]
trials reported substantial reductions in all-cause mortal-
ity, cardiac, and stroke events in patients receiving rami-
pril or losartan, respectively. Because cardiovascular dis-
ease is the single largest cause of morbidity and mortality
among patients with even mild chronic kidney disease,
the HOPE and LIFE trial data provide a further compel-
ling argument for the use of drugs that interrupt the
RAS in patients with kidney disease.
Large randomized clinical studies of the renoprotec-
tive effects of ARBs in nondiabetic kidney disease are
still awaited, but preliminary data suggest that ARBs
are likely to be as effective as ACE inhibitors. In small
studies, ARBs and ACE inhibitors produced similar anti-
hypertensive and antiproteinuric effects in patients with
essential hypertension or chronic kidney disease. One
important advantage of ARBs over ACE inhibitors is
their more favorable side-effect profile, as ARBs are
seldom associated with the cough that may occur in up
to 40% of patients receiving ACE inhibitors. Finally, the
differing effects of ACE inhibitors and ARBs on the
RAS imply that in combination they may have additive
or even synergistic effects, and early evidence appears
to support this contention [35–39].
In the largest combination trial to date, the COOPER-
ATE trial, involving 336 patients with nondiabetic renal
disease treated for 3 years with maximally effective doses
of the ACE inhibitor, trandolapril, or the ARB, losartan,
alone or in combination, the combination clearly was
more effective in reducing progression and urinary pro-
tein excretion than either drug alone [38].
Let’s now take a moment and ask about other new
and novel approaches that might enhance our efforts at
renoprotection. I would like to comment upon a promis-
ing new drug class referred to as vasopeptidase inhibitors
(VPIs). ACE and neutral endopeptidase (NEP) are mech-




ACE inhibitors or ARB treat- Proteinuria 0.5 g/day
ment (consider combination GFR decline 2 mL/min/year
therapy if goals not achieved




therapy (if needed) 130/80 mm Hg
Dietary protein/salt restriction 0.6 to 0.8 g/kg/day and 3 to 5 g/day
Tight glycemic control in
diabetes HbA1C 6.5%
Reduce elevated calcium 
phosphate product Normal values
Lipid-lowering therapy LDL-cholesterol 100 mg/dL
Antiplatelet therapy Thrombosis prophylaxis
Consider correction of anemia Hemoglobin 12 g/dL
Smoking cessation Abstinence
Weight control Ideal body weight




Abbreviations are: ACE, angiotensin-converting enzyme; ARB, angiotensin
receptor blockers; GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; LDL,
low-density lipoprotein.
anistically similar metallopeptidases. ACE cleaves two
peptides from the decapeptide angiotensin I to form the
vasoactive octapeptide, angiotensin II. ACE also degrades
the vasodilator, bradykinin, to inactive metabolites. The
chief substrates for NEP are the vasodilators, bradykinin,
and atrial and brain natriuretic peptides. Thus, a single
molecule capable of inhibiting these two metallopepti-
dases results in reduced angiotensin II–mediated vaso-
constriction as well as enhanced vasodilation due to accu-
mulation of bradykinin, atrial natriuretic peptide, and
brain natriuretic peptide. Taal et al [40] recently evalu-
ated one such dual ACE-NEP inhibitor, omapatrilat, in
comparison to the ACE inhibitor, enalapril, in the rat
partial nephrectomy model. Enalapril extended the time
to high-grade proteinuria well beyond the time course
seen in placebo-treated rats, whereas omapatrilat ex-
tended the period of renoprotection indefinitely, as we
were forced by budgetary considerations to terminate
the study at 1 year when renal injury was still less marked.
Furthermore, the greater renoprotection with omapatri-
lat compared to enalapril was not because of better blood
pressure control as systolic blood pressures were simi-
larly well controlled in both treatment groups. We await
with interest a suitable clinical renoprotection trial of
this new drug class as our rat studies clearly predict that
VPI will provide even greater renoprotection than ACE
inhibition alone.
Based on the evidence reviewed, let me now propose
what might be considered a reasonable comprehensive
strategy for therapy of patients with chronic kidney dis-
ease (Table 1). I think a strong case can be made for
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prescribing an ACE inhibitor, ARB, or both in any pa-
tient with kidney disease in doses sufficient to achieve
two distinct goals, namely, to reduce proteinuria to less
than 0.5 g/day, and to show, by at least twice yearly
checks, that some reliable estimate that GFR is falling
by no more than 2 mL/min/year. Beyond this effort,
other adjunctive treatments should be prescribed to ad-
dress the heightened risk of cardiovascular disease that
exists in all patients with kidney disease. These include
additional antihypertensive drugs as needed to achieve
the Joint National Committee Seventh Report recom-
mended blood pressure target of less than 130/80 [41].
I also recommend moderate dietary protein and salt re-
striction, tight glycemic control in diabetics, statins, aspi-
rin, erythropoietin, and measures to reduce calcium phos-
phorus product, excess body weight, tobacco use, and
exposure to nephrotoxic drugs, including many herbal
remedies and dietary supplements.
Clearly, this aggressive and comprehensive strategy
will require substantial economic outlays from govern-
ment or private insurers, as well as greater involvement
of physicians and other health care professionals in over-
seeing attainment of treatment goals. But hopefully these
added costs and efforts will translate into reduced mor-
bidity and mortality from cardiovascular disease and
fewer patients in need of expensive renal replacement
therapy.
As we move forward with these efforts in regions with
well-developed systems of medical care, let us also ask
whether newer approaches are also needed in medically
less advantaged societies where routine health screening,
secondary and tertiary care facilities, and specialists in
cardiovascular and renal medicine are lacking or in short
supply. In such a setting, is it time to make available a
once-a-day, low-cost cardiovascular and renoprotective
pill, not unlike the all-purpose daily multivitamin so many
of us now take? One such proposal might be an all-in-
one clinically proven effective dose combination pill con-
taining aspirin, lovastatin, and lisinopril, all now generic
and therefore very low in cost. This combination pill, which
I call ASTACE (for aspirin, statin, and ACE inhibitor),
would be no larger than the daily multivitamin we now
take. Clearly, government regulatory approvals would be
required but I believe the time has come to consider this
low-cost, universal approach to vital target organ protec-
tion. An even more ambitious proposal for a polypill
containing folic acid and three antihypertensives (thia-
zide, ARB, and a calcium antagonist) together with low-
dose aspirin and a statin has recently been advocated [42].
CONCLUSION
In less than two decades, the use of ACE inhibitors
and ARBs as therapeutic interventions for slowing renal
disease progression has made the giant leap from labora-
tory to universal clinical practice. In all likelihood, other
novel renoprotective agents will emerge from future lab-
oratory and clinical studies, such as the dual ACE-NEP
inhibitor described, but it is already clear that currently
available strategies not only delay the need for dialysis,
but actually prevent many patients from ever progressing
to ESRD. It may be worth emphasizing that while the
original studies from my laboratory centered upon basic
issues in glomerular capillary physiology, it soon became
evident that our investigations could shed light on mech-
anisms of renal disease progression and on rational ap-
proaches to their interruption. That this has come to
pass serves to reinforce the important and unique role
played by physician-scientists in the pursuit of funda-
mental and initially untargeted biomedical research.
Let me close by again thanking the International Soci-
ety of Nephrology for selecting me to receive the first
AMGEN International Prize which honors me and my
coworkers and also celebrates the currently robust ongo-
ing effort by basic and clinical investigators everywhere
who seek therapies to improve the lives of patients with
chronic kidney disease.
Correspondence to Barry M. Brenner, M.D., Renal Division, Brig-
ham and Women’s Hospital, 75 Francis Street, Boston, MA 02115.
E-mail: Bbrenner@partners.org
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